Last updated 54 days ago

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

388 patients around the world
Available in Spain, Colombia, United States, Mexico, Chile, Peru, Argentina
This study will consist of a 5 week screening period, 48 week treatment period, and a 4 week follow up period for a total of 57 weeks. Each participant will be randomized to receive ESK-001 or placebo for 48 weeks. An open label extension study will be available for those patients who complete the study.
Alumis Inc
388Patients around the world

This study is for people with

Lupus
Systemic lupus erythematosus

Requirements for the patient

To 70 Years
All Gender

Medical requirements

LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy